This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mohler, E. R Articles by Forbes, W. P Search for Related Content PubMed PubMed Citation Articles by Mohler, E. R, III Articles by Forbes, W. P Social Bookmarking                         What's this?

Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication

University of Pennsylvania School of Medicine, Philadelphia, PA, USA, mohlere{at}uphs.upenn.edu

Hugh G Beebe

Jobst Vascular Center, Toledo, OH, USA

Sergio Salles-Cuhna

Jobst Vascular Center, Toledo, OH, USA

Richard Zimet

Otsuka America Pharmaceuticals, Inc, Rockville, MD, USA

Peter Zhang

Otsuka America Pharmaceuticals, Inc, Rockville, MD, USA

Jeffrey Heckman

Otsuka America Pharmaceuticals, Inc, Rockville, MD, USA

William P Forbes

Otsuka America Pharmaceuticals, Inc, Rockville, MD, USA

During exercise, patients with intermittent claudication (IC) have decreased limb arterial blood pressure that recovers during rest. A novel method for assessing dynamic recovery of function is measurement of the hemodynamic response after exercise. Cilostazol (Pletal®), a new agent for the treatment of IC, increases walking distance and may decrease ischemic burden. The objective of this study was to assess the effect of cilostazol versus placebo on hemodynamic measurements after exercise-induced ischemia in patients with IC.

Two double-blind, placebo-controlled studies with similar inclusion/exclusion criteria and duration (24 weeks) were pooled. Patients walked on a treadmill at 2.0 miles/h (3.2 km/h) on a 12.5% grade until the claudication-limited maximal walking distance (MWD) was reached. Anterior and posterior tibial pressures were measured with Doppler ultrasound at baseline and at 1, 5, and 9 min during recovery. Area under the curve (AUC), a measure of the time course of recovery of systolic pressure after exercise-induced ischemia, and ankle-brachial index (ABI) were calculated and compared using analysis of variance (ANOVA).

All three treatment groups (308 patients randomized to cilostazol 100 mg bid, 303 to cilostazol 50 mg bid, and 299 to placebo) had similar baseline characteristics. Mean post-exercise AUC for cilostazol 100 mg and 50 mg bid versus placebo increased by 0.31 (p = 0.001) and 0.26 (p= 0.004), respectively. Mean resting ABI increased by 0.03 (p = 0.0039) and 0.04 (p = 0.0001) in the cilostazol 100 mg and 50 mg bid groups, respectively.

In conclusion, following 24 weeks of treatment, cilostazol increased the ABI at rest and improved the recovery time of ankle pressures post-exercise.

Key Words: ankle-brachial index • cilostazol • claudication

Vascular Medicine, Vol. 6, No. 3, 151-156 (2001)
DOI: 10.1177/1358836X0100600305


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. E. O'Donnell, S. A. Badger, M. A. Sharif, R. R. Makar, I. S. Young, B. Lee, and C.V. Soong The Vascular and Biochemical Effects of Cilostazol in Diabetic Patients With Peripheral Arterial Disease Vascular and Endovascular Surgery, April 1, 2009; 43(2): 132 - 143. [Abstract] [PDF]

				S. S. DeLoach and E. R. Mohler III Peripheral Arterial Disease: A Guide for Nephrologists Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 839 - 846. [Abstract] [Full Text] [PDF]

				A. T. Hirsch, Z. J. Haskal, N. R. Hertzer, C. W. Bakal, M. A. Creager, J. L. Halperin, L. F. Hiratzka, W. R.C. Murphy, J. W. Olin, J. B. Puschett, et al. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1239 - 1312. [Full Text] [PDF]

				S. M Dean Pharmacologic treatment for intermittent claudication Vascular Medicine, November 1, 2002; 7(4): 301 - 309. [Abstract] [PDF]